ACADACADIA PHARMACEUTICALS INC
Pharmaceutical Preparations
- Revenue
- $1.1B
- 12% YoY
- Operating margin
- 9.8%
- 59% YoY
- EBITDA
- $106M
- 54% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired28% of net incomeCash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $484M | $517M | $726M | $958M | $1.1B | 12% |
| Operating income | −$170M | −$224M | −$73M | $231M | $105M | 55% |
| Net income | −$168M | −$214M | −$61M | $226M | $391M | 73% |
| Operating cash flow | −$126M | −$114M | $17M | $158M | $110M | 30% |
| Capex | $1M | $0 | $50K | $523K | $5M | 797% |
| Stock-based comp | $64M | $68M | $66M | $67M | $52M | 22% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $69K · 1
- Net
- −$69K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 50 | 120 |
| FY2024 | — | — | 34 | 91 |
| FY2023 | — | — | 59 | 92 |
| FY2022 | — | — | 30 | 89 |
| FY2021 | — | — | 44 | 99 |